6 December 2024 - More publicly funded medicines are on the way for people with types of breast and lung cancer, and two significant respiratory conditions.

Following public consultation, from 1 January 2025, PHARMAC will fund:

• Osimertinib mesylate (Tagrisso) for patients with a type of advanced non-small cell lung cancer
• Trastuzumab deruxtecan (Enhertu) for patients with HER2 positive metastatic breast cancer
• Palivizumab (Synagis) to prevent respiratory syncytial virus infection in high-risk babies and young children
• Budesonide with eformoterol fumarate dihydrate and glycopyrronium bromide (Breztri Aerosphere) for patients with chronic obstructive pulmonary disease

Read PHARMAC press release